ED90 of Remimazolam Anesthesia Induction in Drug-induced Sleep Endoscopy in Adults

This clinical study determines the optimal dose (specifically the ED90 — the dose effective in 90% of patients) of remimazolam, a short-acting sedative, for inducing sleep during drug-induced sleep endoscopy — a procedure used to evaluate airway obstruction patterns in patients being assessed for snoring or sleep apnea. Researchers are also examining whether the optimal dose differs based on a patient's BMI. Adults aged 18–65 with an ASA health status of I–III, without serious cardiac, respiratory, liver, or kidney disease, are eligible. Participation involves receiving remimazolam sedation during a single scheduled drug-induced sleep endoscopy procedure, with dose adjusted based on responses from earlier participants in the study. This summary was prepared to help patients understand the study in plain language.